ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
Last trade$1.09
Day change+$0.045 (+4.33%)
Day range$1.04 – $1.11
Volume663,743
Market cap$217M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$217.33M
Price / earnings
—
Price / book
-0.24×
Price / sales
280.43×
EV / sales
175.46×
EV / EBITDA
-0.73×
Profitability
Earnings per share
-$0.49
Return on assets
-49.12%
Return on equity
11.39%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0×
Current ratio
5.04×
Quick ratio
5.04×
Cash ratio
2.71×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$167.83M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PROK, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$174K
$150K
$226K
$225K
$217K
$221K
$230K
$76K
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$174K
$150K
$226K
$225K
$217K
$221K
$230K
$76K
Selling, general and administrative
$13.09M
$12.43M
$11.32M
$11.44M
$11.94M
$14.05M
$14.36M
$11.87M
Research and development
$40.85M
$36.1M
$33.84M
$34.16M
$26.82M
$25.88M
$27.26M
$39.78M
Total operating expenses
$53.93M
$48.52M
$45.16M
$45.6M
$38.76M
$39.93M
$41.62M
$51.65M
Operating income
-$53.76M
-$48.37M
-$44.93M
-$45.37M
-$38.54M
-$39.71M
-$41.39M
-$51.57M
Interest expense
-$1K
-$1K
-$15K
-$1K
-$2K
-$1K
$0
-$2K
Income before taxes
-$52.23M
-$46.44M
-$42.62M
-$42.44M
-$35.28M
-$36.12M
-$37.36M
-$46.78M
Income taxes
-$436K
$0
$0
-$1.59M
$560K
$848K
$591K
$1.7M
Net income
-$51.79M
-$46.44M
-$42.62M
-$40.85M
-$35.84M
-$36.97M
-$37.95M
-$48.48M
Net income attributable to common shareholders
-$35.59M
-$28.42M
-$20.04M
-$19.23M
-$16.47M
-$16.55M
-$16.73M
-$21.28M
EBITDA
-$52.09M
-$46.7M
-$43.28M
-$43.53M
-$36.87M
-$38.24M
-$39.79M
-$50M
Basic earnings per share
-$0.17
-$0.15
-$0.14
-$0.13
-$0.12
-$0.13
-$0.13
-$0.17
Diluted earnings per share
-$0.17
-$0.15
-$0.14
-$0.13
-$0.12
-$0.13
-$0.13
-$0.17
Recent news
Company coverage with links to the original publishers.
ProKidney Corp. (PROK) reported a quarterly loss of $0.17 per share, missing consensus estimates of $0.13 by 30.77%. Revenue of $0.17 million also fell short of expectations by 13%. The stock has declined 49.6% year-to-date, significantly underperforming the S&P 500's 11.3% gain. The company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Merck KGaA reported quarterly earnings of $0.24 per share, missing consensus estimates of $0.50 by 52%, though revenues of $6.48 billion exceeded expectations by 5.32%. The stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. ProKidney Corp. is also mentioned as an upcoming earnings reporter in the same Medical-Drugs industry.
ProKidney announced that eight abstracts, including one oral presentation, will be presented at ASN's Kidney Week 2026 in Denver. The abstracts present translational research and a pooled Phase 2 analysis supporting rilparencel's multifactorial mechanism of action for treating chronic kidney disease with type 2 diabetes, demonstrating kidney function stabilization and a strong safety profile.
ProKidney reported full-year 2025 financial results with $270.0 million in cash and cash equivalents, supporting operations into mid-2027. The company achieved significant milestones including FDA alignment on an accelerated approval pathway for rilparencel using eGFR slope as a surrogate endpoint, positive Phase 2 REGEN-007 results, and strong enrollment momentum in the Phase 3 PROACT 1 study. The company expects to complete enrollment for the accelerated approval analysis by mid-2026 and deliver pivotal topline results in Q2 2027.